1. Signaling Pathways
  2. Antibody-drug Conjugate/ADC Related
  3. ADC Linker

ADC Linker

Antibody-drug conjugates (ADCs) consist of a desirable monoclonal antibody, an active cytotoxic drug and an appropriate linker. An appropriate linker between the antibody and the cytotoxic drug provides a specific bridge, and thus helps the antibody to selectively deliver the cytotoxic drug to tumor cells and accurately releases the cytotoxic drug at tumor sites. In addition to conjugation, the linkers maintain ADCs’ stability during the preparation and storage stages of the ADCs and during the systemic circulation period.

The ADCs currently undergoing clinical evaluation contain linkers are mostly classified into two categories: cleavable and noncleavable. Cleavable linkers rely on processes inside the cell to liberate the toxin, such as reduction in the cytoplasm, exposure to acidic conditions in the lysosome, or cleavage by specific proteases within the cell. Noncleavable linkers require proteolytic degradation of the antibody portion of the ADC for release of the cytotoxic molecule, which will retain the linker and the amino acid by which it was attached to the antibody.

The selection of linker is target dependent, based on the knowledge of the internalization and degradation of the antibody-target antigen complex, and a preclinical in vitro and in vivo activity comparison of conjugates. Moreover, the choice of a linker is also influenced by which cytotoxin is used, as each molecule has different chemical constraints, and frequently the drug structure lends itself to a specific linker.

ADC Linker Isoform Specific Products:

  • Cleavable

  • Noncleavable

ADC Linker 相关产品 (139):

Cat. No. Product Name Effect Purity
  • HY-100216
    SPDP 98.45%
    SPDP (SPDP Crosslinker) 是一种短链交联剂,可通过 NHS-酯和吡啶基二硫醇反应性基团与半胱氨酸巯基形成可裂解的 (可还原的) 二硫键,实现胺与巯基的结合。SPDP (SPDP Crosslinker) 是一种谷胱甘肽可切割的连接桥 (ADC linker),用于抗体-药物结合物 (ADCs)。
  • HY-78738
    MC-Val-Cit-PAB 99.69%
    MC-Val-Cit-PAB是可被组织蛋白酶切割的ADC连接桥,用于制备抗体-药物偶联物。 美国FDA批准的药物,如brentuximab vedotin使用了该连接桥。
  • HY-12362
    Val-cit-PAB-OH 99.64%
    Val-cit-PAB-OH 是一种可降解的 ADC linker。
  • HY-41189
    Fmoc-Val-Cit-PAB-PNP
    Fmoc-Val-Cit-PAB-PNP 是一种可降解的多肽前体药物连接子,是抗体偶联药物 (ADC) 的常用连接桥。
  • HY-D0975
    Sulfo-SMCC sodium
    Sulfo-SMCC sodium 是一种常用的异双官能交联剂,是不可降解的 ADC linker,其带有N-羟基琥珀酰亚胺 (NHS) 酯和马来酰亚胺基团,分别与伯胺和巯基反应。
  • HY-W011561
    Boc-NH-C6-Br
    Boc-NH-C6-Br 是一种可切割的连接桥,用于抗体偶联药物 (ADC)。
  • HY-42360
    SMCC
    SMCC 是一种蛋白质交联剂。SMCC 接合抗原耦合脾脏细胞来诱导抗原特异性免疫反应。
  • HY-43869
    Vipivotide tetraxetan Linker
    Vipivotide tetraxetan Linker (PSMA-617 Linker) 是一种有效的不可降解的肽类 Linker,可用于合成 Vipivotide tetraxetan (PSMA-617)。 Vipivotide tetraxetan (PSMA-617) 是用于合成 177Lu-PSMA-617 的配体,177Lu-PSMA-617 是用于治疗前列腺癌的一种放射性分子。
  • HY-20336
    Mc-Val-Cit-PABC-PNP 98.68%
    Mc-Val-Cit-PABC-PNP是用于合成抗体-药物偶联物 (ADCs) 的,可降解的组织蛋白酶连接桥 (ADC linker)。
  • HY-12448
    SPDB 99.30%
    SPDB 是一种谷胱甘肽可切割的连接桥 (ADC linker),用于抗体-药物结合物 (ADCs)。
  • HY-78961
    6-Maleimidohexanoic acid N-hydroxysuccinimide ester 99.96%
    6-Maleimidohexanoic acid N-hydroxysuccinimide ester(ECMS)是抗体偶联药物(ADC)中常用保护基团。
  • HY-114430
    Fmoc-Phe-Lys(Boc)-PAB-PNP 98.67%
    Fmoc-Phe-Lys(Boc)-PAB-PNP 是抗体偶联药物 (ADC) 的常用一种可降解的连接桥。
  • HY-19318
    Fmoc-Val-Cit-PAB 98.13%
    Fmoc-Val-Cit-PAB 是一种可降解的抗体偶联药物 (ADC) 常用连接桥。
  • HY-101159
    Mal-amido-PEG8-C2-acid
    Mal-amido-PEG8-C2-acid (example 142) 是一种不可降解的 ADC 连接桥,信息来自专利 US2018339985。
  • HY-129367
    NO2-SPP
    NO2-SPP 是一种用于制备抗体偶联药物 (ADC) 的可切割连接桥。
  • HY-129375
    SNPB-sulfo-Me
    SNPB-sulfo-Me 是一种用于制备抗体偶联药物 (ADC) 的可切割连接桥。
  • HY-129365
    SNPB
    SNPB 是一种用于制备抗体偶联药物 (ADC) 的可切割连接桥。
  • HY-129352
    Cbz-Phe-(Alloc)Lys-PAB-PNP
    Cbz-Phe-(Alloc)Lys-PAB-PNP 是可用于抗体-药物偶联物 (ADC) 的可切割 linker。
  • HY-129362
    Phe-Lys(Fmoc)-PAB
    Phe-Lys(Fmoc)-PAB是一种组织蛋白酶可切割的 ADC 连接桥 (ADC linker),用于抗体偶联药物 (ADCs)
  • HY-128927
    Mc-Leu-Gly-Arg
    Mc-Leu-Gly-Arg 是一种可降解的醚类 linker,可用于抗体-药物偶联物 (ADC) 研究。
Isoform Specific Products

Your Search Returned No Results.

Sorry. There is currently no product that acts on isoform together.

Please try each isoform separately.